达托霉素
注射用达托霉素说明书
注射用达托霉素说明书一、药品名称：注射用达托霉素二、成分：每支注射用达托霉素含有主要成分达托霉素。
三、性状：本品为无色至浅黄色透明液体。
四、适应症：注射用达托霉素适用于以下疾病的治疗：1. 呼吸道感染：包括肺炎、咽炎、扁桃体炎等；2. 泌尿系感染：包括膀胱炎、尿道感染等；3. 皮肤组织感染：包括疖、蜂窝组织炎等；4. 腹腔感染：包括腹膜炎、急性阑尾炎等；5. 骨关节感染：包括骨髓炎、关节炎等。
五、用法与用量：成人建议用量：根据病情轻重和感染部位的不同，一般每日使用量为0.3g至0.6g，分2次至4次静脉注射。
儿童建议用量：根据儿童体重和感染病情，一般每日使用量为10mg/kg至20mg/kg，分2次至4次静脉注射。
六、不良反应：接受注射用达托霉素治疗的患者中，约有10%的人可能会出现以下不良反应：1. 胃肠道不适：包括恶心、呕吐、腹泻等；2. 皮肤过敏：包括皮疹、瘙痒等；3. 肝功能异常：包括转氨酶升高等；4. 肾功能异常：包括血肌酐升高、尿毒症等。
若出现以上不良反应，应立即停药并咨询医师。
七、禁忌症：以下人群禁止使用达托霉素：1. 对达托霉素过敏者；2. 孕妇、哺乳期妇女禁用。
八、注意事项：1. 根据医生指导合理使用，严格按照剂量和疗程进行治疗；2. 注意药品的保存环境，避免阳光直射；3. 请勿超量使用本品。
九、药物相互作用：在与其他药物同时应用时，需谨慎慎重，如与其他青霉素类药物、链霉素类药物或保护肝脏药物同时使用时，可能会增加肝、肾功能异常的风险。
十、规格：每支注射用达托霉素的规格为10ml/支。
十一、生产企业：本药品由XXX制药公司生产。
十二、有效期：请查看药品包装上标示的有效期。
备注：本说明书仅供医生参考，患者使用本药品需在医生指导下进行。
如有药品使用上的疑问，请咨询医师。
注射用达托霉素说明书
注射用达托霉素注射用达托霉素，适应症为金黄色葡萄球菌（包括甲氧西林敏感和甲氧西林耐药）导致的伴发右侧感染性心内膜炎的血流感染（菌血症）。
如果确定或怀疑的病原体包括革兰阴性菌或厌氧菌，则临床上可采用联合抗菌治疗。
在患有由金黄色葡萄球菌引起的左侧感染性心内膜炎的患者中，尚未证实克必信的有效性。
在金黄色葡萄球菌血流感染的患者中进行的克必信临床试验，包含来自左侧感染性心内膜炎患者的资料；在这些患者中，疗效不佳（见临床研究）。
在人工瓣膜心内膜炎或脑膜炎患者中，尚未对克必信进行评价。
若患者患有持续性或复发性金黄色葡萄球菌感染，或临床疗效欠佳，应该重复进行血培养。
如果金黄色葡萄球菌的血培养为阳性，则应采用标准操作规程进行该菌株的MIC药敏试验，并且应进行诊断性评估，以排除罕见的感染病灶存在（见注意事项）。
本药不适用于治疗肺炎。
应获得适当的标本进行微生物学检查，以便分离和鉴定引起感染的病原体，并测定其对达托霉素的敏感性。
当等待试验结果时，可以采用经验性治疗。
根据微生物学检查结果，应对抗菌治疗进行调整。
为了延缓耐药性的发展，并维持本药和其它抗菌药的疗效，克必信应仅用来治疗被确定或强烈怀疑由敏感菌引起的感染。
在获得培养和药敏结果后，应考虑选择或调整抗菌治疗。
缺乏这些资料的情况下，当地的流行病学和敏感性趋势有助于经验性治疗的抗菌药物选择。
目录1. 1成份2. 2适应症3. 3用法用量1. 4不良反应5禁忌2.3. 6注意事项1. 7包装成份达托霉素适应症金黄色葡萄球菌（包括甲氧西林敏感和甲氧西林耐药）导致的伴发右侧感染性心内膜炎的血流感染（菌血症）。
如果确定或怀疑的病原体包括革兰阴性菌或厌氧菌，则临床上可采用联合抗菌治疗。
在患有由金黄色葡萄球菌引起的左侧感染性心内膜炎的患者中，尚未证实克必信的有效性。
在金黄色葡萄球菌血流感染的患者中进行的克必信临床试验，包含来自左侧感染性心内膜炎患者的资料；在这些患者中，疗效不佳（见临床研究）。
达托霉素
10~12mg/kg/24h，疗程为﹥6周(IIb-C)；当DAP用于上述感染治疗时，可考虑与头孢他洛林或 氨苄西林合用，特别是在持续菌血症或肠球菌对DAP的MIC值位于敏感折点内但较高时(如 3μg/mL，敏感折点为≦4μg/mL)(IIb-C)。但在体外试验中庆大霉素、利福平和替加环素与DAP 合用不具协同效应，应避免选用
[3] Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. European Heart Journal, 2015
英国抗菌化疗协会(BSAC)和中华医学会指南
①经验性治疗
②葡萄球菌NVE
9
③葡萄球菌PVE
[4] Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67: 269–289
手工筛选标准： DAP疗程≥3d，基 线CPK正常、至少1次CPK随访、开 始DAP治疗 后的7d内无手术史、无
其他引起CPK ↑原因
无任何肌病相 关证据
1:1匹配，匹配原则：DAP疗程相等， 整个疗程无CPK增高及肌病相关症状
2024年达托霉素市场发展现状
达托霉素市场发展现状引言达托霉素是一种广谱的抗生素，常用于治疗多种细菌引起的感染，如呼吸道感染、皮肤和软组织感染等。
它属于大环内酯类药物，具有良好的抗菌活性和渗透性，在临床上应用广泛。
本文旨在探讨达托霉素市场发展现状，并对未来的市场趋势进行分析。
市场规模与增长趋势近年来，达托霉素市场呈现出稳步增长的态势。
根据市场研究数据显示，2019年全球达托霉素市场规模达到X亿美元，预计到2025年将增长至Y亿美元。
市场规模的快速增长主要受以下几个因素的影响：1.高效抗菌谱：达托霉素对多种细菌具有较强的抗菌活性，包括耐药菌株。
如MRSA（金黄色葡萄球菌耐甲氧西林菌株）等细菌引起的感染，达托霉素表现出较高的疗效，这为其市场需求提供了坚实基础。
2.药物疗效的改进：随着科学技术的进步和药物研发的不断推进，达托霉素的疗效逐渐得到了提高。
新的配方和剂型的引入，也为患者提供了更为便捷和有效的治疗选择。
3.全球老龄化人口增加：随着全球老龄化程度的加深，慢性疾病的发病率上升，导致感染性疾病的发生率也相应增加。
而达托霉素在老年人中的应用较为广泛，因此市场需求呈现出明显增长势头。
市场竞争格局目前，达托霉素市场的竞争格局较为激烈。
除了原研企业的产品，也出现了多个仿制药企业投放到市场。
主要的市场竞争因素包括价格、产品质量、市场渠道和品牌影响力等。
1.原研企业的优势：原研企业在药物研发和生产上具有较高的技术实力和经验，他们可以依靠自身的强大研发平台，维持与竞争对手的差异化竞争。
2.仿制药的崛起：仿制药在价格上具有明显优势，这使得一些患者和医疗机构倾向于选择仿制药。
一些仿制药企业通过降低成本，在市场竞争中占据一定的份额。
3.品牌影响力：在医药市场中，知名原研企业具有较高的品牌影响力，这使得一些患者和医生更加信任其产品的疗效和质量。
因此，品牌建设和品牌推广对于企业在市场竞争中具有重要作用。
市场发展机遇与挑战虽然达托霉素市场面临一些机遇，但也存在一些挑战需要应对。
达托霉素的作用与功效
达托霉素的作用与功效达托霉素是一种广谱抗生素，常用于治疗呼吸道和泌尿道感染等疾病。
它的作用机制是通过抑制细菌蛋白质合成来杀死细菌或抑制它们的生长。
达托霉素被广泛用于临床治疗，并被认为是安全有效的药物之一。
以下是达托霉素的作用和功效的详细介绍。
1. 抗菌谱广泛：达托霉素对多种细菌具有优良的抗菌活性。
它对革兰氏阳性菌和阴性菌都有杀灭作用，包括耐药菌株。
因此，达托霉素被广泛应用于治疗和预防细菌感染。
2. 高渗透性：达托霉素在体内的分布均匀，可以迅速进入各种组织和体液。
它可以通过细胞膜进入细菌细胞，并在细菌内部积累。
达托霉素对细菌的渗透性能够使其在细菌感染时迅速达到治疗浓度，发挥有效的杀菌作用。
3. 持久的杀菌活性：达托霉素的半衰期较长，使其具有持续的治疗效果。
通过一天一次的给药，可以保持达到有效治疗浓度达12-24小时，从而实现对细菌的持续杀菌作用。
4. 广泛用于呼吸道感染：达托霉素在治疗呼吸道感染方面表现出色。
它可以用于治疗细菌性鼻窦炎、扁桃体炎、中耳炎、支气管炎和肺炎等上呼吸道和下呼吸道感染。
达托霉素能迅速进入呼吸道组织并在肺组织中积累，从而实现有效的杀菌作用。
5. 治疗泌尿道感染：达托霉素也被广泛应用于治疗泌尿道感染。
它可以用于治疗尿路感染、肾盂肾炎和前列腺炎等疾病。
达托霉素进入泌尿道组织后能够在尿液中高浓度存在，从而对泌尿道感染的细菌起到杀菌作用。
6. 高效克服耐药性：达托霉素对耐药细菌株表现出高度的活性。
它不仅对传统的对青霉素、头孢菌素和万古霉素产生耐药性的细菌表现出杀菌作用，而且对耐甲氧西林金黄色葡萄球菌（MRSA）和产大肠杆菌（ESBL）的细菌产生的耐药性也表现出优良的杀菌效果。
7. 老年和儿童患者的良好耐受性：与其他一些广谱抗生素相比，达托霉素在老年和儿童患者中的耐受性良好。
它对胃肠道的刺激作用较轻，不会引起严重的胃肠道反应，这对老年和儿童患者来说非常重要。
总之，达托霉素是一种广谱抗生素，具有广谱的抗菌活性，可用于呼吸道和泌尿道感染的治疗。
达托霉素临床综述
达托霉素临床试验综述1.临床试验与文献总结1.1 临床试验总结本申报品种为原料药，属注册分类3（其注射剂属化药注册分类6），根据我国相关法律法规可以免临床。
1.2 临床试验文献总结1.2.1 生物药剂学研究总结本品种的制剂为静脉注射剂，生物利用度为100。
尚未见生物等效性试验资料。
，2，3，41.2.2 临床药理学研究总结1人体药代动力学（PK）研究、药效学（PD）研究：达托霉素获FDA 批准按照4mg/kg 的剂量使用，可在体内表现出线性良好的药代动力学曲线，血药浓度-时间曲线严格遵循两室模型的一级消除动力学，最大血药浓度为57g/ml，曲线下面积AUC 为494g×h/ml，消除半衰期t 为8～9h，表观分布容积为0.09L/kg，血清蛋白结合率约92，抗生素后效应为3～6h。
该药主要通过肾脏消除，三分之二的药物以原药形式排泄，没有发现结构性和毒性代谢。
此外，达托霉素在体内不能透过血脑屏障。
健康志愿者日注射本品1～8mg/kg，药动学数据提示呈线性代谢，首次注射4、6 和8mg/kg 剂量后最大血药浓度分别为55、86 和116 g/mL，蛋白结合率为90～94，平均半衰期t1/2为7.74±0.63小时。
24 小时尿中原型药物排泄为59.7±10.2，注射4mg/kg 本品后的1 和2 小时，皮肤炎性疱液中的药物浓度分别是49.4 和14.5 g/mL。
达托霉素是从一株发酵的链霉菌属玫瑰色孢子中提取出来的具有独特环结构的脂肽类抗生素。
它由一个十碳烷侧链与一个环状β氨基酸肽链N-末端的色氨酸连接而成。
达托霉素具有在体外抗所有革兰阳性菌的作用。
这些菌包括耐药菌，如耐万古霉素的肠球菌（VRE）、耐甲氧西林的金葡菌（MRSA）、甲氧西林敏感金葡菌（MSSA）、糖肽类敏感的金葡菌（GISA）、凝固酶阴性的葡萄球菌（CNS）和耐青霉素的肺炎链球菌（PRSP），对于这些耐药菌可选择的抗生素很少。
达托霉素
Generic Name】Daptomycin Injection,Powder,Lyophilized,for Solution[FDA]【Brand Name】Cubicin【Active Ingredients】达托霉素【Description】CUBICIN contains daptomycin, a cyclic lipopeptide antibacterial agent derived from the fermentation of Streptomyces roseosporus. The chemical name isN-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthrani loyl-L-alanine ε1-lactone. The chemical structure is:The empirical formula is C72H101N17O26; the molecular weight is 1620.67. CUBICIN issupplied as a sterile, preservative-free, pale yellow to light brown, lyophilized cake containing approximately 900 mg/g of daptomycin for intravenous (IV) use following reconstitution with 0.9% sodium chloride injection. The only inactive ingredient is sodium hydroxide, which is used in minimal quantities for pH adjustment. Freshly reconstituted solutions of CUBICIN range in color from pale yellow to light brown.【Clinical Pharmacology】PharmacokineticsThe mean (SD) pharmacokinetic parameters of daptomycin at steady-state following IV administration of 4 to 12 mg/kg q24h to healthy young adults are summarized in Table 1.Daptomycin pharmacokinetics were generally linear and time-independent at doses of 4 to 12 mg/kg q24h. Steady-state trough concentrations were achieved by the third daily dose. The mean (SD) steady-state trough concentrations attained following administration of 4, 6, 8, 10, and 12 mg/kg q24h were 5.9 (1.6), 6.7 (1.6), 10.3 (5.5), 12.9 (2.9), and 13.7 (5.2) µg/mL, respectively.Table 1. Mean (SD) CUBICIN Pharmacokinetic Parameters in HealthyVolunteers at Steady-StatePharmacokinetic Parameters*Dose†AUC0-24t1/2V ss CL T C max(mg/kg) (µg*h/mL)(h) (L/kg) (mL/h/kg) (µg/mL)4 (N=6) 494 (75) 8.1(1.0) 0.096(0.009)8.3 (1.3) 57.8 (3.0)6 (N=6) 632 (78) 7.9(1.0) 0.101(0.007)9.1 (1.5) 93.9 (6.0)8 (N=6) 858 (213) 8.3(2.2) 0.101(0.013)9.0 (3.0) 123.3(16.0)10 (N=9) 1039 (178) 7.9(0.6) 0.098(0.017)8.8 (2.2) 141.1(24.0)12 (N=9) 1277 (253) 7.7(1.1) 0.097(0.018)9.0 (2.8) 183.7(25.0)*AUC0-24, area under the concentration-time curve from 0 to 24 hours; t½, terminalelimination half-life; Vss , volume of distribution at steady-state; CLT, plasmaclearance; Cmax, maximum plasma concentration.†Doses of CUBICIN in excess of 6 mg/kg have not been approved.DistributionDaptomycin is reversibly bound to human plasma proteins, primarily to serum albumin, in a concentration-independent manner. The overall mean binding ranged from 90 to 93%.In clinical studies, mean serum protein binding in subjects with CLCR≥30 mL/min was comparable to that observed in healthy subjects with normal renalfunction. However, there was a trend toward decreasing serum protein binding amongsubjects with CLCR<30 mL/min (87.6%), including those receiving hemodialysis (85.9%) and continuous ambulatory peritoneal dialysis (CAPD) (83.5%). The protein binding of daptomycin in subjects with hepatic impairment (Child-Pugh B) was similar to that in healthy adult subjects.The volume of distribution at steady-state (Vss) of daptomycin in healthy adult subjects was approximately 0.10 L/kg and was independent of dose.MetabolismIn vitro studies with human hepatocytes indicate that daptomycin does not inhibit or induce the activities of the following human cytochrome P450 isoforms: 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4. In in vitro studies, daptomycin was not metabolized by human liver microsomes. It is unlikely that daptomycin will inhibit or induce the metabolism of drugs metabolized by the P450 system.In 5 healthy young adults after infusion of radiolabeled 14C-daptomycin, the plasma total radioactivity was similar to the concentration determined by microbiological assay. In a separate study, no metabolites were observed in plasma on Day 1 following administration of CUBICIN at 6 mg/kg to subjects. Inactive metaboliteshave been detected in urine, as determined by the difference in total radioactive concentrations and microbiologically active concentrations. Minor amounts of three oxidative metabolites and one unidentified compound were detected in urine. The site of metabolism has not been identified.ExcretionDaptomycin is excreted primarily by the kidney. In a mass balance study of 5 healthy subjects using radiolabeled daptomycin, approximately 78% of the administered dose was recovered from urine based on total radioactivity (approximately 52% of the dose based on microbiologically active concentrations) and 5.7% of the dose was recovered from feces (collected for up to 9 days) based on total radioactivity.Because renal excretion is the primary route of elimination, dosage adjustment is necessary in patients with severe renal insufficiency (CLCR<30 mL/min) (see DOSAGE AND ADMINISTRATION).Special PopulationsRenal InsufficiencyPopulation derived pharmacokinetic parameters were determined for infected patients (complicated skin and skin structure infections and S. aureus bacteremia) and noninfected subjects with varying degrees of renal function (Table 2). Plasmaclearance (CLT ), elimination half-life (t1/2), and volume of distribution (Vss) weresimilar in patients with complicated skin and skin structure infections compared with those with S. aureus bacteremia. Following the administration of CUBICIN 4 mg/kg q24h, the mean CLTwas 9%, 22%, and 46% lower among subjects and patients withmild (CLCR 50–80 mL/min), moderate (CLCR30–<50 mL/min), and severe (CLCR<30 mL/min)renal impairment, respectively, than in those with normal renal function (CLCR>80mL/min). The mean steady-state systemic exposure (AUC), t1/2, and Vssincreased withdecreasing renal function, although the mean AUC was not markedly different for patients with CLCR30–80 mL/min compared with those with normal renal function. Themean AUC for patients with CLCR<30 mL/min and for patients on hemodialysis (dosed post-dialysis) was approximately 2 and 3 times higher, respectively, than for patients with normal renal function. Following the administration of CUBICIN 4mg/kg q24h, the mean Cmax ranged from 60 to 70 µg/mL in patients with CLCR≥30 mL/min,while the mean Cmax for patients with CLCR<30 mL/min ranged from 41 to 58 µg/mL. Themean Cmaxranged from 80 to 114 µg/mL in patients with mild-to-moderate renal impairment and was similar to that of patients with normal renal function after the administration of CUBICIN 6 mg/kg q24h. In patients with renal insufficiency, both renal function and creatine phosphokinase (CPK) should be monitored more frequently. CUBICIN should be administered following the completion of hemodialysis on hemodialysis days (see DOSAGE AND ADMINISTRATION for recommendeddosage regimens).Table 2. Mean (SD) Daptomycin Population Pharmacokinetic Parameters Following Infusion of 4 mg/kg or 6 mg/kg to Infected Patients and Noninfected Subjects with Varying Degrees of Renal FunctionRenal Functiont1/2*V ss*CL T*AUC0-∞*AUC ss†C min,ss†(h) (L/kg) (mL/h/kg) (µg*h/mL)(µg*h/mL)(µg*h/mL)4 mg/kg 4 mg/kg 4 mg/kg 4 mg/kg 6 mg/kg 6 mg/kgNote: CL CR, creatinine clearance estimated using the Cockcroft-Gault equation with actual body weight; AUC0-∞, area under theconcentration-time curve extrapolated to infinity; AUC ss, area under the concentration-time curve calculated over the 24-hour dosing interval at steady-state; C min,ss, trough concentration at steady-state; NA, not applicable.Normal 9.39(4.74) 0.13(0.05)10.9 (4.0) 417 (155) 545 (296) 6.9 (3.5)(CL CR >80mL/min)N=165 N=165 N=165 N=165 N=62 N= 61Mild Renal Impairment 10.75(8.36)0.12(0.05)9.9 (4.0) 466 (177) 637 (215) 12.4 (5.6)(CL CR 50−80mL/min)N=64 N=64 N=64 N=64 N=29 N=29Moderate Renal Impairment 14.70(10.50)0.15(0.06)8.5 (3.4) 560 (258) 868 (349) 19.0 (9.0)(CL CR 30−<50mL/min)N=24 N=24 N=24 N=24 N=15 N=14Severe Renal Impairment 27.83(14.85)0.20(0.15)5.9 (3.9) 925 (467) 1050, 892 24.4, 21.4(CL CR <30mL/min)N=8 N=8 N=8 N=8 N=2 N=2Hemodialysis 29.81(6.13) 0.15(0.04)3.7 (1.9) 1244 (374) NA NAN=21 N=21 N=21 N=21*Parameters obtained following a single dose from patients with complicated skin and skin structure infections and healthy subjects.†Parameters obtained at steady-state from patients with S. aureus bacteremia. Hepatic InsufficiencyThe pharmacokinetics of daptomycin were evaluated in 10 subjects with moderatehepatic impairment (Child-Pugh Class B) and compared with healthy volunteers (N=9) matched for gender, age, and weight. The pharmacokinetics of daptomycin were not altered in subjects with moderate hepatic impairment. No dosage adjustment is warranted when administering CUBICIN to patients with mild-to-moderate hepatic impairment. The pharmacokinetics of daptomycin in patients with severe hepatic insufficiency have not been evaluated.GenderNo clinically significant gender-related differences in daptomycin pharmacokinetics have been observed. No dosage adjustment is warranted based on gender when administering CUBICIN.GeriatricThe pharmacokinetics of daptomycin were evaluated in 12 healthy elderly subjects (≥75 years of age) and 11 healthy young controls (18 to 30 years of age). Following administration of a single 4 mg/kg IV dose, the mean total clearance of daptomycinincreased approximately 58% in was reduced approximately 35% and the mean AUC0-∞elderly subjects compared with young healthy subjects. There were no differences . No dosage adjustment is warranted for elderly patients with normal renal in Cmaxfunction.ObesityThe pharmacokinetics of daptomycin were evaluated in 6 moderately obese (Body Mass Index [BMI] 25 to 39.9 kg/m2) and 6 extremely obese (BMI ≥40 kg/m2) subjects and controls matched for age, sex, and renal function. Following administration of a single 4 mg/kg IV dose based on total body weight, the plasma clearance of daptomycin normalized to total body weight was approximately 15% lower in moderately obese subjects and 23% lower in extremely obese subjects compared with nonobeseof daptomycin increased approximately 30% in moderately obese controls. The AUC0-∞and 31% in extremely obese subjects compared with nonobese controls. The differences were most likely due to differences in the renal clearance of daptomycin. No dosage adjustment of CUBICIN is warranted in obese subjects.PediatricThe pharmacokinetics of daptomycin in pediatric populations (<18 years of age) have not been established.Drug-Drug InteractionsDrug-drug interaction studies were performed with CUBICIN and other drugs that arelikely to be either coadministered or associated with overlapping toxicity. AztreonamIn a study in which 15 healthy adult subjects received a single dose of CUBICIN 6mg/kg IV, aztreonam 1 g IV, and both in combination, the Cmax and AUC0-∞of daptomycinwere not significantly altered by aztreonam; the Cmax and AUC0-∞of aztreonam alsowere not significantly altered by daptomycin. No dosage adjustment of either antibiotic is warranted when coadministered.TobramycinIn a study in which 6 healthy adult males received a single dose of CUBICIN 2 mg/kgIV, tobramycin 1 mg/kg IV, and both in combination, the mean Cmax and AUC0-∞ofdaptomycin increased 12.7% and 8.7%, respectively, when administered withtobramycin. The mean Cmax and AUC0-∞of tobramycin decreased 10.7% and 6.6%,respectively, when administered with CUBICIN. These differences were not statistically significant. The interaction between daptomycin and tobramycin with a clinical dose of CUBICIN is unknown. Caution is warranted when CUBICIN is coadministered with tobramycin.WarfarinIn 16 healthy subjects, concomitant administration of CUBICIN 6 mg/kg q24h for 5 days followed by a single oral dose of warfarin (25 mg) had no significant effect on the pharmacokinetics of either drug and did not significantly alter the INR (International Normalized Ratio) (see PRECAUTIONS, Drug Interactions).SimvastatinIn 20 healthy subjects on a stable daily dose of simvastatin 40 mg, administration of CUBICIN 4 mg/kg IV q24h for 14 days (N=10) was not associated with a higher incidence of adverse events than in subjects receiving placebo once daily (N=10) (see PRECAUTIONS, Drug Interactions).ProbenecidConcomitant administration of probenecid (500 mg 4 times daily) and a single doseof CUBICIN 4 mg/kg IV did not significantly alter the Cmax and AUC0-∞of daptomycin. Nodosage adjustment of CUBICIN is warranted when CUBICIN is coadministered with probenecid.MICROBIOLOGYDaptomycin is an antibacterial agent of a new class of antibiotics, the cyclic lipopeptides. Daptomycin is a natural product that has clinical utility in the treatment of infections caused by aerobic Gram-positive bacteria. The in vitro spectrum of activity of daptomycin encompasses most clinically relevantGram-positive pathogenic bacteria. Daptomycin retains potency againstantibiotic-resistant Gram-positive bacteria, including isolates resistant to methicillin, vancomycin, and linezolid.Daptomycin exhibits rapid, concentration-dependent bactericidal activity against Gram-positive organisms in vitro. This has been demonstrated both by time-kill curves and by MBC/MIC ratios (minimum bactericidal concentration/minimum inhibitory concentration) using broth dilution methodology. Daptomycin maintained bactericidal activity in vitro against stationary phase S. aureus in simulated endocardial vegetations. The clinical significance of this is not known.Mechanism of ActionThe mechanism of action of daptomycin is distinct from that of any other antibiotic. Daptomycin binds to bacterial membranes and causes a rapid depolarization of membrane potential. This loss of membrane potential causes inhibition of protein, DNA, and RNA synthesis, which results in bacterial cell death.Mechanism of ResistanceAt this time, no mechanism of resistance to daptomycin has beenidentified. Currently, there are no known transferable elements that confer resistance to daptomycin.Cross-ResistanceCross-resistance has not been observed with any other antibiotic class.Interactions with Other AntibioticsIn vitro studies have investigated daptomycin interactions with other antibiotics. Antagonism, as determined by kill curve studies, has not been observed. In vitro synergistic interactions of daptomycin with aminoglycosides, β-lactam antibiotics, and rifampin have been shown against some isolates of staphylococci (including some methicillin-resistant isolates) and enterococci (including some vancomycin-resistant isolates).Complicated Skin and Skin Structure Infection (cSSSI) StudiesThe emergence of daptomycin non-susceptible isolates occurred in 2 infected patients across the set of Phase 2 and pivotal Phase 3 clinical trials. In one case, a non-susceptible S. aureus was isolated from a patient in a Phase 2 study who received CUBICIN at less than the protocol-specified dose for the initial 5 days of therapy. In the second case, a non-susceptible Enterococcus faecalis was isolated from a patient with an infected chronic decubitus ulcer enrolled in a salvage trial.S. aureus Bacteremia/Endocarditis and Other Post-Approval StudiesIn subsequent clinical trials, non-susceptible isolates were recovered. S. aureus was isolated from a patient in a compassionate-use study and from 7 patients in the S. aureus bacteremia/endocarditis study (see PRECAUTIONS). An E. faecium was isolated from a patient in a VRE study.Daptomycin has been shown to be active against most isolates of the following microorganisms both in vitro and in clinical infections, as described in the INDICATIONS AND USAGE section.Aerobic and facultative Gram-positive microorganisms:Enterococcus faecalis (vancomycin-susceptible isolates only)Staphylococcus aureus (including methicillin-resistant isolates)Streptococcus agalactiaeStreptococcus dysgalactiae subsp. equisimilisStreptococcus pyogenesThe following in vitro data are available, but their clinical significance is unknown. Greater than 90% of the following microorganisms demonstrate an in vitro MIC less than or equal to the susceptible breakpoint for daptomycin versus the bacterial genus. The efficacy of daptomycin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials.Aerobic and facultative Gram-positive microorganisms:Corynebacterium jeikeiumEnterococcus faecalis (vancomycin-resistant isolates)Enterococcus faecium (including vancomycin-resistant isolates)Staphylococcus epidermidis (including methicillin-resistant isolates) Staphylococcus haemolyticusSusceptibility Testing MethodsSusceptibility testing by dilution methods requires the use of daptomycin susceptibility powder. The testing of daptomycin also requires the presence of physiological levels of free calcium ions (50 mg/L of calcium, using calcium chloride) in Mueller-Hinton broth medium.Dilution TechniqueQuantitative methods are used to determine antimicrobial MICs. These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure1, 2 based on a broth dilution method or equivalent using standardized inoculum and concentrations of daptomycin. The use of the agar dilution method is not recommended with daptomycin2. The MICs should be interpreted according to the criteria in Table 3.A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable.Table 3. Susceptibility Interpretive Criteria forDaptomycinPathogenBroth Dilution MIC* (µg/mL)S I RNote: S, Susceptible; I, Intermediate; R, Resistant.Staphylococcus aureus≤1(†) (†)(methicillin-susceptible andmethicillin-resistant)Streptococcus pyogenes, Streptococcusagalactiae,≤1(†) (†)and Streptococcus dysgalactiaesubsp. equisimilisEnterococcus faecalis≤4(†) (†)(vancomycin-susceptible only)*The MIC interpretive criteria for S. aureus and E. faecalis are applicable only to tests performed by broth dilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L; the MIC interpretive criteria for Streptococcus spp. other than S. pneumoniae are applicable only to tests performed by broth dilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L, supplemented with 2 to 5% lysed horse blood, inoculated with a direct colony suspension and incubated in ambient air at 35ºC for 20 to 24 hours.†The current absence of data on daptomycin-resistant isolates precludes defining any categories other than “Susceptible.” Isolates yielding test results suggestive of a “Non-Susceptible” category should be retested, and if the result is confirmed, the isolate should be submitted to a reference laboratory for further testing.Diffusion TechniqueQuantitative methods that require measurement of zone diameters have not been shown to provide reproducible estimates of the susceptibility of bacteria to daptomycin. The use of the disk diffusion method is not recommended with daptomycin2, 3.Quality ControlStandardized susceptibility test procedures require the use of quality control microorganisms to control the technical aspects of the procedures. Standard daptomycin powder should provide the range of values noted in Table 4. Quality control microorganisms are specific strains of organisms with intrinsic biological properties relating to resistance mechanisms and their genetic expression within bacteria; the specific strains used for microbiological quality control are not clinically significant.Table 4. Acceptable Quality ControlRanges for Daptomycin to Be Used inValidation of Susceptibility TestResultsQuality Control StrainBroth DilutionMIC Range*(μg/mL) Enterococcusfaecalis ATCC292121−4Staphylococcusaureus ATCC 292130.25−1Streptococcuspneumoniae ATCC49619†0.06−0.5*The quality control ranges for S. aureus and E. faecalis are applicable only to tests performed by broth dilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L; the quality control ranges for S. pneumoniae are applicable only to tests performed by broth dilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L, supplemented with 2 to 5% lysed horse blood, inoculated witha direct colony suspension and incubated in ambient air at 35ºC for 20 to 24 hours.†This organism may be used for validation of susceptibility test results when testing Streptococcus spp. other than S. pneumoniae.【Animal Pharmacology】In animals, daptomycin administration has been associated with effects on skeletal muscle with no changes in cardiac or smooth muscle. Skeletal muscle effects were characterized by degenerative/regenerative changes and variable elevations in CPK. No fibrosis or rhabdomyolysis was evident in repeat-dose studies up to the highest doses tested in rats (150 mg/kg/day) and dogs (100 mg/kg/day). The degree of skeletal myopathy showed no increase when treatment was extended from 1 month to up to 6 months. Severity was dose-dependent. All muscle effects, including microscopic changes, were fully reversible within 30 days following cessation of dosing.In adult animals, effects on peripheral nerve (characterized by axonal degeneration and frequently accompanied by significant losses of patellar reflex, gag reflex, and pain perception) were observed at doses higher than those associated with skeletal myopathy. Deficits in the dogs’ patellar reflexes were seen within 2 weeks of the start of treatment at 40 mg/kg (9 times the human Cat the 6 mg/kgmaxq24h dose), with some clinical improvement noted within 2 weeks of the cessation of dosing. However, at 75 mg/kg/day for 1 month, 7/8 dogs failed to regain full patellar reflex responses within the duration of a 3-month recovery period. In a separate study in dogs receiving doses of 75 and 100 mg/kg/day for 2 weeks, minimal residual histological changes were noted at 6 months after cessation of dosing. However, recovery of peripheral nerve function was evident.Tissue distribution studies in rats have shown that daptomycin is retained in the kidney but appears to only minimally penetrate across the blood-brain barrier following single and multiple doses.【Clinical Studies】Complicated Skin and Skin Structure InfectionsAdult patients with clinically documented cSSSI (Table 10) were enrolled in two randomized, multinational, multicenter, investigator-blinded studies comparing CUBICIN (4 mg/kg IV q24h) with either vancomycin (1 g IV q12h) or ananti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g IV per day). Patients known to have) bacteremia at baseline were excluded. Patients with creatinine clearance (CLCR between 30 and 70 mL/min were to receive a lower dose of CUBICIN as specified in the protocol; however, the majority of patients in this subpopulation did not have the dose of CUBICIN adjusted. Patients could switch to oral therapy after a minimum of 4 days of IV treatment if clinical improvement was demonstrated.One study was conducted primarily in the United States and South Africa (study 9801), and the second (study 9901) was conducted at non-US sites only. Both studies were similar in design but differed in patient characteristics, including history of diabetes and peripheral vascular disease. There were a total of 534 patients treated with CUBICIN and 558 treated with comparator in the two studies. The majority (89.7%) of patients received IV medication exclusively.The efficacy endpoints in both studies were the clinical success rates in the intent-to-treat (ITT) population and in the clinically evaluable (CE) population. In study 9801, clinical success rates in the ITT population were 62.5% (165/264) in patients treated with CUBICIN and 60.9% (162/266) in patients treated with comparator drugs. Clinical success rates in the CE population were 76.0% (158/208) in patients treated with CUBICIN and 76.7% (158/206) in patients treated with comparator drugs. In study 9901, clinical success rates in the ITT population were 80.4% (217/270) in patients treated with CUBICIN and 80.5% (235/292) in patients treated with comparator drugs. Clinical success rates in the CE population were 89.9% (214/238) in patients treated with CUBICIN and 90.4% (226/250) in patients treated with comparator drugs.The success rates by pathogen for microbiologically evaluable patients are presented in Table 11.Table 10. Invest igator’s Primary Diagnosis in the cSSSI Studies(Population: ITT)Study 9801 Study 9901 Pooled PrimaryDiagnosisCUBICIN/Comparator*CUBICIN/Comparator* CUBICIN/Comparator* N=264/N=266 N=270/N=292 N=534/N=558Wound Infection 99 (37.5%)/116(43.6%)102 (37.8%)/108(37.0%)201 (37.6%)/224(40.1%)Major Abscess 55 (20.8%)/43(16.2%)59 (21.9%)/65(22.3%)114 (21.3%)/108(19.4%)Ulcer Infection 71 (26.9%)/75(28.2%)53 (19.6%)/68(23.3%)124 (23.2%)/143(25.6%)Other Infection†39 (14.8%)/32(12.0%)56 (20.7%)/51(17.5%)95 (17.8%)/83(14.9%)*Vancomycin or anti-staphylococcal semi-synthetic penicillins.†The majority of cases were subsequently categorized as complicated cellulitis, major abscesses, or traumatic wound infections.Table 11. Clinical Success Rates by InfectingPathogen, Primary Comparative cSSSI Studies(Population: Microbiologically Evaluable)Success Rate Pathogen CUBICIN Comparator*n/N (%) n/N (%)Methicillin-susceptible Staphylococcus aureus (MSSA)†170/198(85.9)180/207(87.0)Methicillin-resistant Staphylococcus aureus (MRSA)†21/28(75.0)25/36 (69.4)Streptococcus pyogenes79/84(94.0)80/88 (90.9)Streptococcus agalactiae23/27(85.2)22/29 (75.9)Streptococcus dysgalactiaesubsp. equisimilis8/8 (100) 9/11 (81.8)Enterococcus faecalis (vancomycin-susceptible only)27/37(73.0)40/53 (75.5)*Vancomycin or anti-staphylococcal semi-synthetic penicillins.†As determined by the central laboratory.S. aureus Bacteremia/EndocarditisThe efficacy of CUBICIN in the treatment of patients with S. aureus bacteremia was demonstrated in a randomized, controlled, multinational, multicenter open-label study. In this study, adult patients with at least one positive blood culture for S. aureus obtained within 2 calendar days prior to the first dose of study drug and irrespective of source were enrolled and randomized to either CUBICIN (6 mg/kg IV q24h) or standard of care [anti-staphylococcal semi-synthetic penicillin 2 g IV q4h (nafcillin, oxacillin, cloxacillin, or flucloxacillin) or vancomycin 1 g IV q12h, both with initial gentamicin 1 mg/kg IV every 8 hours for first 4 days]. Of the patients in the comparator group, 93% received initial gentamicin for a median of 4 days compared with 1 patient (<1%) in the CUBICIN group. Patients with prosthetic heart valves, intravascular foreign material that was not planned for removal within 4 days after the first dose of study medication, severe neutropenia, known osteomyelitis, polymicrobial bloodstream infections, creatinine clearance <30 mL/min, and pneumonia were excluded.Upon entry, patients were classified for likelihood of endocarditis using the modified Duke criteria (Possible, Definite, or NotEndocarditis). Echocardiography, including a transesophageal echocardiogram。
达托霉素演示文稿1
5月2日胸部CT
达托霉素 500mg ivd
MRSA
白细胞计数变化曲线
30 25
白细胞计数（*10^9）
20 15 10 5
22.91 21.54
24.01 18.17
16.42 13.7 14.48 13.64 9.298.39 系列1
达托霉素500mg IVD QD
0 2014- 2014- 2014- 2014- 2014- 2014- 2014- 2014- 20144-1 4-6 4-11 4-16 4-21 4-26 5-1 5-6 5-11
治疗革兰阳性球菌感染的抗生素
万古霉素 皮肤及软 组织感染 肺炎 导管相关 血流感染 血流感染 ++
替考拉宁 ++
达托霉素 +++
利奈唑胺 +++
替加环素 +++
++ ++
++ ++
+++
+++ +
+ +
++
++
+++
+
+
IDSA指南对不同MRSA感染的药物选择的建议
感染类型 蜂窝织炎 药物 克林霉素，TMP-SMZ， 多西环素，米诺环素， 利奈唑胺 万古霉素，利奈唑胺， 达托霉素，替拉万星， 克林霉素 万古霉素，达托霉素 建议 口服，目标菌为CA-MRSA；
时间
IDSA MRSA 指南: 对于住院的cSSTI成年患者的建议
• cSSTI 包括: 深层软组织感染、手术/创伤性伤口感染、严重脓肿、蜂窝 织炎和溃疡及烧伤感染 • cSSTI的治疗包括: 手术清创+ 广谱抗生素(覆盖MRSA)
达托霉素
如果无法避免与喷洒Ｅ ａ ｉｔ ｖｍ ｓ 的手臂的直接接触，则建议妇女穿上能
够遮 盖 用 药 部 位 的衣 服 。一 旦 发 生接 触 ，则 应 尽快 用 肥 皂和 水 冲 洗
Ａｆｕ ｉ流 感 疫 苗 ｌｒａ
关键词 ： 发热 热性惊厥
７ Ｏ 月３ 日，美 国ＦＡ Ｄ对季 节性流 感疫 苗Ｍｌｒａ ｕ ｉ的产 品说 明书 “ 告 警
促、呼吸 困难，严重的可以导致进行性 呼吸衰竭，如果没有及时发 现并适当治疗可能会致死。
和注意事项 ”部分进行 了更改，提醒医护人员，在澳大利亚，Ｍｌｒａ ｕｉ
６ 中国处方药 ２ １． Ｏ ０ ０｝ ００ ＠Ｎ ． １ ０ ］
Ｆ Ａ 已发 表 的达 托 霉 素 相 关 的嗜 酸 粒 细 胞 肺 炎 的病 例 报 告 进 Ｄ对 行 了回顾 ，并 根据 Ｆ Ａ 不 良反 应报 告 系 统对 达 托 霉 素 的上 市 后 不 良 Ｄ的
ＦＡ Ｄ 建议 ，患者 用 药 时应 确保 儿 童及 宠物 不 会接 触 到用 药 部位 ，
Ｓａｅｏ 否增 力， ｔ］ｖ是 口 血管事件 风险， 估完 成后将 及时向公众 公布。 评
拉莫蔓嗪
关键词： 无菌性脑膜 炎
８ ２ 月１ 日，美国Ｆ Ａ Ｄ 发出警告 ，用于治疗癫痫发作和双相情感障 碍的药物拉莫三嗪可能引发无菌性脑膜炎。 无菌性脑膜炎是指覆盖脑和脊髓的脑脊膜 的无菌性炎症，可由 病毒、毒物、某些疫苗 、自身免疫性疾病和某些药物 引起，症状包 括头痛、发热、颈项强直、恶心 、呕吐、皮疹和光过敏，某些情况
巴联用。 ２０ 年６ ０３ 月被批准 ，￣２０年１月，估计已有 １４ｏｏ 患者接受Ｓａｅｏ ０９ ０ ５ ｏ￣Ｊ ｔｌｖ治疗。 虽然左旋多巴也存 肌梗死、 心律失常、 高血压及心悸等报道 ， 但以前的临床试验并没有显示 Ｓａｅｏ 肌梗死、 ｔｌｖ￣， 卒 血管死亡方面与其有差别。
达托霉素高产菌种和生产工艺技术
达托霉素(Daptomycin)高产菌种和生产工艺达托霉素（Daptomycin，Cubicin）是自链霉菌(S.reseosporus)发酵液中提取得到的一个环酯肽类物质，它不仅具有新颖的化学结构，且其作用模式也与任一已获准抗生素不同：本品能在多个方面破坏细菌细胞膜功能，由此迅速杀死革兰阳性菌。
本品除能作用于大多数临床相关革兰阳性菌外，更重要的是在体外对已呈甲氧西林（Methicillin）、万古霉素和利奈唑胺等耐药性分离菌株仍具强力活性。
本品现被批准用于治疗下列革兰阳性体外敏感菌所致并发性皮肤及皮肤结构感染：包括耐甲氧西林菌在内的金黄色葡萄球菌、酿脓链球菌、无乳链球菌、停乳链球菌亚种似马链球菌和对万古霉素敏感粪肠球菌。
达托霉素具有可以赋予其临床优势的数项独特性质。
首先，它的作用机制与现已上市的各类抗菌药物都不相同，这意味着达托霉素将不会受到来自其它抗生素所致交叉耐药性的影响。
其次，达托霉素已经显现能在体外迅速抑制大多数临床重要革兰阳性球菌，包括耐甲氧西林金黄色葡萄球菌、耐万古霉素粪肠球菌和耐万古霉素金黄色葡萄球菌。
而此对其用于危重感染患者具有非常重要的临床意义。
第三，与传统抗生素至少一日2次给药相比，达托霉素仅需一日1次用药，剂量方案明显简化并可有效降低医疗成本支出。
最后，达托霉素似也存在更优的不良反应表现，这使它能够用于治疗不能耐受其它抗生素治疗患者。
达托霉素的产品规格：（1）外观、色泽 白色结晶粉末（2）含量（纯度）（HPLC）： 98.5 ≥%（3）β-异构体 0.1 ≤%（4）内酯物 0.1 ≤%（5）脱水物 0.1 ≤%（6）含水量 0.1≤%（7）单一杂质 0.1≤%（8）总有关杂质 0.5≤%（9）残留溶剂 10≤ppm （10）重金属 10 ≤ppm （11）炽灼残渣 0.3 ≤%达托霉素的工艺技术：发酵水平：1.7-2.0g/L发酵时间：260-270小时收率：〉50%生产菌：Streptomyces roseosporus技术水平：中试以上。
达托霉素的作用与功效
达托霉素的作用与功效达托霉素是一种广谱抗生素，它可用于治疗多种感染症，包括呼吸道感染、皮肤感染、尿路感染等。
本文将详细介绍达托霉素的作用机制、药理特点以及临床应用等方面，以便读者更好地了解和使用该药物。
一、达托霉素的作用机制达托霉素的作用机制主要与其抑制细菌蛋白质合成有关。
它能够与细菌的30S亚单位结合，阻止靶菌在合成蛋白质的过程中附着tRNA到mRNA上，从而使细菌的蛋白质合成受到抑制。
此外，达托霉素还能够阻断细菌核糖体的转位运动，从而干扰蛋白质的合成。
二、达托霉素的药理特点1.药物代谢特点：达托霉素在体内代谢非常缓慢，其血药浓度维持时间较长，使得一次每日（或每两天一次）给药即可维持疗效。
2.体内分布特点：达托霉素在体内广泛分布，能够较好地穿过血脑屏障，进入中枢神经系统，从而对治疗脑膜炎等中枢神经系统感染有一定效果。
3.药物消除特点：达托霉素通过肝脏酶CYP3A4代谢酶被代谢，然后由肾脏排泄。
肾功能不全的患者，应适当减量。
三、达托霉素的临床应用1.呼吸道感染：达托霉素对于肺炎链球菌、流感嗜血杆菌、半乳糖杆菌等引起的复杂性呼吸道感染具有较好的疗效。
尤其对于广谱β内酰胺酶阳性的致病菌具有一定的敏感性，能够避免氨基酮类抗生素的使用。
2.皮肤和软组织感染：达托霉素对于革兰阳性链球菌、葡萄球菌等引起的皮肤和软组织感染显示出很好的疗效。
尤其对于降低敏感性的金黄色葡萄球菌（MRSA）感染，达托霉素显示出了比其他药物更好的治疗效果。
3.泌尿道感染：达托霉素对于大肠杆菌、肠球菌等引起的泌尿道感染具有很好的疗效。
因其在尿液中的浓度较高，可通过尿液达到高浓度。
同时，其广谱抗菌谱又能够覆盖多种引起泌尿道感染的致病菌。
4.屈光不正引起的感染：对于角膜炎等屈光不正所致的感染疾病，达托霉素通过给药后迅速在眼部组织内达到较高浓度，可有效治疗并预防感染。
5.其他感染：达托霉素还可以用于治疗骨关节感染、中枢神经系统感染、腹腔感染等。
达托霉素在临床使用中的药物不良反应评价
临床医药文献电子杂志Electronic Journal of Clinical Medical Literature2019 年 第 6 卷第 40 期2019 Vol.6 No.40170达托霉素在临床使用中的药物不良反应评价刘智勇，汪忠祥（新疆昭苏县人民医院，新疆 伊犁 835600）【摘要】目的 分析达托霉素在临床使用中的药物不良反应发生的一般性规律及发生特点，为临床合理使用该药物提供参考依据。
方法 选取2016年1月至2018年1月我国知网、万方、医院数据图书馆、维普检索的关于达托霉素发生不良反应的相关文献，并根据文献，针对其中关于患者使用达托霉素后出现不良反应的情况、时间、类型等做相关汇总分析。
结果 选取文献共40篇，汇总的达托霉素不良反应患者135例，发生不良反应时，其病症可涉及到全身的多个系统，这些系统主要包括呼吸系统、肌肉骨骼系统、过敏反应等。
结论 达托霉素引发的不良反应会涉及多个系统，应慎重使用达托霉素。
【关键词】达托霉素；不良反应；效果评价【中图分类号】R9 【文献标识码】A 【文章编号】ISSN.2095-8242.2019.40.170.02达托霉素是一种环脂肽类抗生素，具有亲脂性和亲水性，当其处于游离钙离子下，机体内的蛋白会同达托霉素亲水性因子氨基酸尾链发生结合，致使细胞膜出现迅速老化现象，进而对机体的遗传信息合成产生抑制作用，使机体的遗传信息不能表达，促进有害细菌死亡。
本研究主要收集关于达托霉素发生不良反应的相关文献，对所发生不良反应的关联性特征进行分析研究，期望可为临床上合理的使用达托霉素而提供一些有用性的参考依据。
1 数据来源数据主要选取2016年1月至2018年1月我国知网、万方、医院数据图书馆、维普检索得出，关键词主要输入“达托霉素”、“不良反应"。
2 文献统计分析将检索为同一病例的文献剔除后，使用统计学法提取相关文献中有关的数据，对文献作者、文献类型及提取的患者一般资料（包括性别、疾病类型），药物使用方法、药物名称服用天数，药物引起的不良反应的基本时间、类型及具体病症进行统计、记录及研究分析[1]。
达托霉素在重症感染中的地位
GPC感染的诊断
临床诊断病原学诊断
达托霉素-独特的快速杀菌作用机制
与其他抗菌药物不同几乎没有交叉耐药与革兰阳性菌细胞膜不可逆结合插入细胞膜依赖Ca2+使细胞膜快速去极化泵出钾离子破坏离子浓度梯度导致细菌非溶解性死亡细菌生物系统多处受损抑制DNA、RNA和蛋白质合成
按2008年 CLSI 非脑膜炎肺炎链球菌的青霉素的批准标准 S≤2、I=4、R≥8mg/L, 儿童中PSSP由2006年的94%下降到2011年的73.6%；PISP 和PRSP分别由2006年的2.8%和3.7%上升到2011年的13.6%和12.9%成人中的PSSP的检出率(＞90%)高于儿童
(1)
29.1
(2)
21.2
7.9
6.7
1.3
2009
14
12668
32.5
(1)
29.8
(2)
20.5
7.9
5.4
1.2
2010
14
13568
32.8
(1)
29.8
(2)
22.7
7.0
6.0
1.4
2011
15
16872
35.5
(1)
27.2
(2)
19.8
6.6
7.2
1.2
2012
15
20354
36.1
(1)
30.6
(2)
18.3
6.6
5.8
2.4
中国CHINET监测网 历年来监测的革兰阳性菌
金葡菌(1)、肠球菌属细菌(2)、凝(-)葡萄球菌(3)、肺链(4)、溶血链球菌(5)、草链(6)金葡菌、肠球菌属细菌的检出率有下降、凝(-葡萄球菌、肺链的检出率有上升趋势
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
达托霉素
达托霉素是由Lilly（礼来）公司最初研究,在2012年湖北威德利化学科技有限公司通过高新技术仿制环脂肽类抗生素--达托霉素（Daptomycin）,达托霉素是继万古霉素之后第二代糖肽类抗生素药，湖北威德利化学科技有限公司通过链霉菌发酵液中提取得到，具有不同的化学结构，而且其作用与其他抗生素不同，是万古霉素有效的替代者。
基本信息：
[产品名称]：达托霉素
[中文同义名]：达妥霉素
[英文名]：Daptomycin
[CAS No]：103060-53-3
[分子量]：1620.67
[分子式]：C72H101N17O26
[质量标准]：企业出口标准
[包装规格]：100克/袋，1KG/铝听。
[质量标准]：含量≥93.0%
产品优势：我司研发达托霉素的外观是黄.色或者淡黄.色精细无定形粉末，在达托霉素HPLC 和达托霉素IR以及达托霉素UV均符合国外药典注册标准规定，达托霉素比旋度是+17°到+28°，达托霉素酸碱度PH呈偏酸性，在3到5之间，我司的达托霉素原料产品质量高于国外注册标准，如炽灼残渣国外标准规定是≤4%，而我司可以达到≤2%以下。
含量更是高于规定的93%以上，达到98%以上。
更详细的其他指标信息可以向我司销售经理索要详细质检报告。
储存建议：湖北威德利化学科技有限公司建议达托霉素于密闭容器储存，温度在-20℃到5℃之间，如需运输，请保持温度为2℃到8℃。